Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents - Wikidata - awgldk - TriplyDB

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

http://www.wikidata.org/entity/Q26764833

about

An overview of quinoline as a privileged scaffold in cancer drug discovery.

P2860

Q39235281-79287B1A-647C-49CD-B288-D352AC7B3DDB

P2860

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

http://www.wikidata.org/entity/Q26764833

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@ast

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@en

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@nl

type

label

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@ast

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@en

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@nl

prefLabel

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@ast

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@en

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@nl

P1433

Q26764833-99C66EDE-B962-4DBA-A597-90619DC4E0F2

P1476

Q26764833-D5FB145F-05D4-4637-AB80-8E17F3FFD59A

P2093

Q26764833-EEDC09AB-D8DC-4322-B7BD-902F74A65340

P2860

Q26764833-02666C66-8F22-4D33-915C-7E874630683B

Q26764833-02E1AC81-4FE6-41A6-ABCE-0C780A02167C

Q26764833-04B9A55C-A0A9-47BA-9719-7BCF57347A58

Q26764833-059F219F-B7AC-4B49-8397-ABA08E2F784F

Q26764833-08E43043-4521-41B6-8F8B-D195346E578C

Q26764833-0C840099-2E76-4A86-88AA-8E013E09787E

Q26764833-0D9F4ADC-0EB9-42C5-9A6D-01914B9D1372

Q26764833-0EB23EF4-E00A-4533-940E-1411B4472B41

Q26764833-1818EF4A-97FD-4BB7-BE05-1D46E87F3233

Q26764833-198FE934-9E4F-44C2-A201-BB909FBFECDB

P2888

Q26764833-F61D9962-CF17-4042-9809-68EA06E7DB49

P304

Q26764833-A085FAD0-4846-4311-90EC-93FF8E6790A4

P31

Q26764833-A37160D7-AA33-41C7-8104-3014F8A08FCC

P356

Q26764833-4E7DF2E1-0ACD-4553-B964-78F6D5E3490A

P407

Q26764833-9FA0B1F4-35C6-4614-A845-C24B19D73B04

P433

Q26764833-1816F18E-61D4-495F-8A8D-EAEF4303C66B

P478

Q26764833-8CD173B8-4CB7-46D7-BBC9-78DBA90EA14B

P50

Q26764833-A6B6FAFA-0437-4D05-BA6A-573919FBF2AC

P577

Q26764833-AE69C0C2-6ED8-4048-BEC1-E3DE644EF786

P6179

Q26764833-1755B010-0736-4EF5-A3F2-8D1054B23C51

P698

Q26764833-A713B9F0-73A5-45C3-9A9F-1FB3A37912D2

P921

Q26764833-E3E6E5BD-5F01-4A7E-87A7-0B5F63975A14

P932

Q26764833-02463410-4CE4-40F2-A687-FF052739348E

P356

S11899-016-0299-0

P1433

Current hematologic malignancy reports

P1476

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

@en

P2093

Joseph Maly

http://www.w3.org/2001/XMLSchema#string

P2860

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals

The direct recruitment of BLNK to immunoglobulin alpha couples the B-cell antigen receptor to distal signaling pathways

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

Comparison of human B cell antigen receptor complexes: membrane-expressed forms of immunoglobulin (Ig)M, IgD, and IgG are associated with structurally related heterodimers

From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Targets of B-cell antigen receptor signaling: the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway and the Rap1 GTPase

P2888

s11899-016-0299-0

P304

52-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-016-0299-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

James S Blachly

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044697809

http://www.w3.org/2001/XMLSchema#string

P698

26893063

http://www.w3.org/2001/XMLSchema#string

P921

P932

4969081

http://www.w3.org/2001/XMLSchema#string